New challenges for 21st century clinical trials

Joensuu H. , Kellokumpu-Lehtinen PL , Bono P. et al. Adjuvant docetaxel or vinorelebine with or without trastuzimab for breast cancer. N Engl J Med 2006; 354: 809—20.

Simon R. Targets for treatment success. Nature Clin Pract Oncol 2006; 3: 1.

Simon R. Bioinformatics in cancer therapeutics-hype or hope? Nature Clinic Pract Oncol 2005; 2: 223.

Gail M. , Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41: 361.

Papadopoulos N. , Kinzler KW , Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnol 2006; 24: 985—95.

Maitournam A. , Simon R. On the efficiency of targeted clinical trials . Stat Med 2005; 24: 329—39.

Simon R. , Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials: Supplement and Correction. Clin Cancer Res 2006; 12: 3229.

Simon R. , Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials . Clin Cancer Res 2005; 10: 6759—63.

Freidlin B. , Simon R. Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients . Clin Cancer Res 2005; 11: 7872—78.

Simon R. , Wang SJ Use of genomic signatures in therapeutics development. Pharmacogen J 2006; 6: 166—73.

Fda. Guidance for industry: Pharmacogenomics data submissions. Rockville MD, Food and Drug Administration, U.S. Department of Health and Human Services.

Burkowski T. , Molenberghs G. , Buyse M. , Geys H. , Renard D. Validation of surrogate endpoints in multiple randomized clinical trials with failure time end points. J Royal Stat Soc C 2001; 50: 405.

Korn EL , Albert PS , McShane LM. Assessing surrogates as trial endpoints using mixed models. Stat Med 2004; 24:163—82.

Torri V. , Simon R. , Russek-Cohen E. , Midthune D. , Freidman M. Relationship of response and survival in advanced ovarian cancer patients treated with chemotherapy. J Natl Cancer Inst 1992; 84: 407.

Simon R. When is a genomic classifier ready for prime time? Nature Clin Pract: Oncol 2004; 1: 2—3.

Simon R. A roadmap for developing and validating therapeutically relevant genomic classifiers . J Clin Oncol 2005; 23: 7332—41.

Simon R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 2005; 97: 866—67.

Simon R. Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. J Natl Cancer Inst 2006; 98: 1169—71.

Romond EH , Perez EA , Bryant J. , Suman VJ , Geyer CE , Davidson NE , Al E. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N Engl J Med 2005; 353: 1673—84.